Form 8-K - Current report:
SEC Accession No. 0001171843-25-004094
Filing Date
2025-06-25
Accepted
2025-06-25 07:31:28
Documents
15
Period of Report
2025-06-20
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_062525.htm   iXBRL 8-K 17019
2 EXHIBIT 10.1 exh_101.htm EX-10.1 31175
3 PRESS RELEASE exh_991.htm EX-99.1 11574
  Complete submission text file 0001171843-25-004094.txt   270349

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE gnw-20250101.xsd EX-101.SCH 3402
5 XBRL DEFINITION FILE gnw-20250101_def.xml EX-101.DEF 26066
6 XBRL LABEL FILE gnw-20250101_lab.xml EX-101.LAB 35956
7 XBRL PRESENTATION FILE gnw-20250101_pre.xml EX-101.PRE 24702
17 EXTRACTED XBRL INSTANCE DOCUMENT f8k_062525_htm.xml XML 3312
Mailing Address 701 VETERANS CIRCLE WARMINSTER PA 18974
Business Address 701 VETERANS CIRCLE WARMINSTER PA 18974 604-419-3200
Arbutus Biopharma Corp (Filer) CIK: 0001447028 (see all company filings)

EIN.: 980597776 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34949 | Film No.: 251070970
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)